Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4440-4448

  Cheng, Fengdong ^a   Wang, Hongwei ^a   Horna, Pedro ^a   Wang, Zi ^a   Shah, Bijal ^a   Sahakian, Eva ^a   Woan, Karrune V ^a   Villagra, Alejandro ^a   Pinilla Ibarz, Javier ^a   Sebti, Said ^a   Smith, Mitchell ^b   Tao, Jianguo ^a   Sotomayor, Eduardo M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPA 7; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CHLORINE COMPOUNDS; DISEASE PROGRESSION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MICE; MICE, SCID; PLATINUM COMPOUNDS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84865779996     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3619     Document Type: Article

References (50)

1. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001;98:1070-7.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
3. Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood 2006;107:2871-8.
4. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-94.
5. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-14.
6. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-13.
7. Fuchs EJ, Bedi A, Jones RJ, Hess AD. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 1995;55:463-6.
8. Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multi-drug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 1999;93:1831-7.
9. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005;11:986-91.
10. Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-71.
11. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-9.
12. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 2008;83:144-9.
13. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
14. Sano S, Itami S, Takeda K, Tarutani M, Yamaquchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999;18:4657-68.
15. Takeda K, Clausen BE, Kaisho T, Tusjimura T, Terada N, Förster I, et al. Enhanced Th1 activityanddevelopment ofchronic enterocholitis inmice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39.
16. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24:315-27.
17. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003;19:425-36.
18. Kirberg J, Baron A, Jakob S, Rolink A, Karjalainen K, von Boehmer H. Thymic selection of CD8+ single positive cellswith a class IImajor histocompatibility complex-restricted receptor. J Exp Med 1994;180:25-34.
19. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998;76:34-40.
20. Staveley-O' Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
21. Smith MR, Joshi I, Jin F, Al-Saleem T. Murine model for mantle cell lymphoma. Leukemia 2006;20:891-3.
22. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
23. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63.
24. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
25. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biologicalactivity. Mol Cancer Ther 2004;3:261-9.
26. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21.
27. Wang M, Zhang L, Han Xiaohong, Yang Jing, Qian Jianfei, Hong Sungyoul, et al. Atiprimod inhibits the growth of mantel cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathway. Blood 2007;109:5455-62.
28. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, et al. Over-expression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001;61:3276-80.
29. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005;175:4338-46.
30. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-35.
31. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994;367:425-8.
32. Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004;172:803-11.
33. Chaperot L, Plumas J, Jacob MC, Bost F, Molens JP, Sotto JJ, et al. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999;27:479-88.
34. Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001;61:1107-12.
35. Adler AJ, Marsh DW, Yochum GS, Guzzo JL, Nigam A, Nelson WG, et al. CD4(+) T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998;187:1555-64.
36. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implication for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-20.
37. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
38. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL, Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004;200:1581-92.
39. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240.
40. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, et al. Immunization with granulocyte-macrophage colony-stimulating factor- transduced, but not B7-1-transduced, lymphoma cells primes idiotype- specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-65.
41. Maric M, Chen L, Sherry B, Liu Y.A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha. J Immunol 1997;159:360-8.
42. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia 2001;15:1451-7.
43. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002;62:3195-9.
44. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 2006;116:90-100.
45. Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, et al. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett 2010;131:126-30.
46. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 2003;199:84-9.
47. Baran-Marszak F, Boukhiar M, Harel S, Laquiller C, Roger C, Gressin R, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica 2010;95:1865-72.
48. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
49. Madan R, Demircik F, Surianarayanan S, Allen JL, Divanovic S, Trompette A, et al. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J Immunol 2009;183:2312-20.
50. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011;71:3182-8.